Acute effects of alpha-1 adrenoceptor antagonist, doxazosin on circulating vasoactive hormones. 1994

F Veglio, and D Schiavone, and A Rossi, and L Chiandussi
Dipartimento di Medicina e Oncologia Sperimentale, University of Turin, Italy.

The acute effects of doxazosin, a new selective alpha-1 adrenergic blocking agent, on blood pressure, heart rate, and on some circulating vasoactive hormones, such as plasma renin activity, catecholamines, serotonin and endothelin-1 in ten healthy normotensive volunteers and eight moderate-severe essential hypertensives were studied. Two milligrams doxazosin was administered orally in randomised fashion as compared to placebo and the acute effects were evaluated one half to four hours later. Doxazosin did not reduce blood pressure and did not increase heart rate in normotensive subjects as compared to placebo. A significant decrease in blood pressure was found in hypertensives after doxazosin (p < 0.01), without change in heart rate. Simultaneously, doxazosin did not modify plasma renin activity, catecholamines, serotonin and endothelin-1 concentrations both in normotensive and hypertensive subjects when compared with placebo administration. Thus, it appears that doxazosin does not influence local and systemic vasopressor hormones involving in the regulation of blood pressure. In conclusion, the lack of effects on plasma vasoactive factors confirms the selective alpha-1 postsynaptic antagonism of doxazosin and an effective antihypertensive action in the treatment of essential hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006728 Hormones Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. Hormone,Hormone Receptor Agonists,Agonists, Hormone Receptor,Receptor Agonists, Hormone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D017292 Doxazosin A prazosin-related compound that is a selective alpha-1-adrenergic blocker. Doxazosin Mesylate,1 (4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine,Alfamedin,Apo-Doxazosin,Cardular,Cardura,Carduran,Carduran Neo,Diblocin,Doxa-Puren,DoxaUro,Doxacor,Doxagamma,Doxamax,Doxatensa,Doxazomerck,Doxazosin AL,Doxazosin AZU,Doxazosin Apogepha,Doxazosin Heumann,Doxazosin Klast,Doxazosin Monohydrochloride,Doxazosin Stada,Doxazosin Von Ct,Doxazosin beta,Doxazosin findusFit,Doxazosin-Wolff,Doxazosin-ratiopharm,Doxazosina Alter,Doxazosina Cinfa,Doxazosina Combino Pharm,Doxazosina Geminis,Doxazosina Normon,Doxazosina Pharmagenus,Doxazosina Ratiopharm,Doxazosina Ur,Gen-Doxazosin,Jutalar,MTW-Doxazosin,Novo-Doxazosin,Progandol Neo,UK-33274,Uriduct,Zoxan,ratio-Doxazosin,Apo Doxazosin,Ct, Doxazosin Von,Doxa Puren,Doxazosin Wolff,Doxazosin ratiopharm,Gen Doxazosin,MTW Doxazosin,Mesylate, Doxazosin,Monohydrochloride, Doxazosin,Neo, Carduran,Novo Doxazosin,Ratiopharm, Doxazosina,UK 33274,UK33274,Von Ct, Doxazosin,ratio Doxazosin

Related Publications

F Veglio, and D Schiavone, and A Rossi, and L Chiandussi
January 1986, British journal of clinical pharmacology,
F Veglio, and D Schiavone, and A Rossi, and L Chiandussi
January 2009, Oncology research,
F Veglio, and D Schiavone, and A Rossi, and L Chiandussi
June 1983, British journal of clinical pharmacology,
F Veglio, and D Schiavone, and A Rossi, and L Chiandussi
January 1988, Xenobiotica; the fate of foreign compounds in biological systems,
F Veglio, and D Schiavone, and A Rossi, and L Chiandussi
May 1992, Clinical pharmacy,
F Veglio, and D Schiavone, and A Rossi, and L Chiandussi
February 1989, Journal of clinical pharmacology,
F Veglio, and D Schiavone, and A Rossi, and L Chiandussi
October 1996, European journal of pharmacology,
F Veglio, and D Schiavone, and A Rossi, and L Chiandussi
April 2004, The British journal of dermatology,
F Veglio, and D Schiavone, and A Rossi, and L Chiandussi
January 1994, European journal of pharmacology,
F Veglio, and D Schiavone, and A Rossi, and L Chiandussi
October 2005, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!